Corcept Therapeutics Incorporated vs Taro Pharmaceutical Industries Ltd.: Annual Revenue Growth Compared

Pharma Giants: Divergent Revenue Paths from 2014 to 2023

__timestampCorcept Therapeutics IncorporatedTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 201426551000759285000
Thursday, January 1, 201550286000862944000
Friday, January 1, 201681321000950751000
Sunday, January 1, 2017159201000879387000
Monday, January 1, 2018251247000661913000
Tuesday, January 1, 2019306486000669893000
Wednesday, January 1, 2020353874000644769000
Friday, January 1, 2021365978000548970000
Saturday, January 1, 2022401858000561347000
Sunday, January 1, 2023482375000572952000
Monday, January 1, 2024629182000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: Revenue Growth Over a Decade

In the competitive landscape of pharmaceuticals, Corcept Therapeutics Incorporated and Taro Pharmaceutical Industries Ltd. have showcased contrasting revenue trajectories from 2014 to 2023. Corcept Therapeutics, starting with a modest revenue base, has experienced a remarkable growth of over 1,700% by 2023, reflecting its strategic advancements and market penetration. In contrast, Taro Pharmaceutical, despite its larger revenue base, has seen a decline of approximately 25% over the same period, indicating potential market challenges or strategic shifts.

The data reveals that while Corcept's revenue surged from $26.6 million in 2014 to $482.4 million in 2023, Taro's revenue decreased from $759.3 million to $572.9 million. This divergence highlights the dynamic nature of the pharmaceutical industry, where innovation and adaptability are key to sustained growth. Missing data for 2024 suggests ongoing developments that could further influence these trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025